News Agency
The Times

New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia

  • Written by PR Newswire
New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia

NSW and Myeloid entered into a partnership in February 2023 to launch state-of-the-art GMP manufacturing RNA facility

CAMBRIDGE, Mass., Sept. 12, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors....

Read more: New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion